ClinicalTrials.gg
Enrolling by invitationNCT06637254Updated Dec 24, 2024

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma

A Phase 2 interventional study of HSK31858 and Placebo in Bronchial Asthma, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Planned enrollment
85th of 182
219 · median 203
Started
2024
with 37 others
Phase 2
39 of 251
19 open now
Primary completion
2026-03
later than 26 of 95 live
Registered
180th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 85th largest by planned enrollment of the 182 interventional ones that give a count, is one of 38 that started in 2024, is one of 39 in phase 2, reaches primary completion later than 26 of the 95 other live ones, and was the 180th registered.

Asthma

4,846 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma

03

Conditions studied

  • Bronchial Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form.
  2. Male or female patients aged ≥18 and ≤75 years at screening, weighing ≥40 kg.
  3. Diagnosis of typical asthma and their history of asthma is ≥12 months at screening (provide a traceable record of asthma diagnosis).
  4. Have been treated for ≥3 consecutive months prior to screening with a moderate-to-high daily dose of inhaled (ICS) in combination with at least one other asthma-controlling medication, and have remained stable for ≥1 month prior to screening.
  5. Have had ≥1 acute exacerbation of asthma in the 12 months prior to screening.
  6. Screening period (V1) pre-bronchodilator \<80% of predicted value.
  7. Screening period (V1) 5-item Asthma Control Questionnaire (ACQ-5) ≥ 1.5.
  8. Screening period (V1) blood eosinophil count \<150/μL.
  9. Female subjects with fertility or male subjects whose partner is a female with fertility must agree to have no plans to have children and to use voluntarily from the time of signing the informed consent form until 3 months after the last dose. All females of must have a negative screening pregnancy test.
  10. Subjects are able to communicate well with the investigator and are able to complete the study in accordance with the protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Requires long-term oral maintenance therapy.
  2. Subjects also have other lung diseases, including , bronchiectasis, and pulmonary fibrosis, not dominated by asthma as determined by the investigator.
  3. Comorbid with other diseases that are and may affect lung function, including but not limited to pleural disease, mediastinal disease, diaphragmatic lesions, myasthenia, and thoracic deformities.
  4. History of : subjects with basal cell carcinoma, limited squamous cell carcinoma of the skin, or cervical carcinoma in situ will be allowed to enter the study if curative treatment has been completed for at least 12 months prior to signing the form; subjects with other malignancies will be allowed to enter the study if curative treatment has been completed for at least 5 years prior to signing the informed consent form.
  5. Patients who have experienced any degree of acute exacerbation of asthma or are experiencing an acute exacerbation of asthma within 4 weeks prior to screening.
  6. Active infection or acute infection requiring systemic anti-infective therapy within 4 weeks prior to screening.
  7. Presence of any severe and/or uncontrolled medical condition that, in the judgement of the investigator, affects the safety of the subject or interferes with the evaluation of the medication, including, but not limited to: severe neurological disease, history of serious mental disorders, major cardiovascular disease, diabetes mellitus that is poorly controlled on standardized therapy, presence of prolonged interval or cardiac arrhythmia, or immunodeficiency disorders.
  8. Subjects with a history of liver disease or currently receiving treatment for liver disease during the screening period, including but not limited to acute and chronic hepatitis, cirrhosis or liver failure.
  9. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg, and/or diastolic blood pressure ≥ 100 mmHg at screening or baseline).
  10. Abnormal screening and baseline laboratory tests:

    1. White blood cell count \< 3 × 109/L, or \< 1.5 × 109/L, or \< 70 × 109/L, or \< 90 g/L;
    2. (ALT) > 2 × (upper limit of normal), or aspartate aminotransferase (AST) > 2 × ULN, or total (TBIL) > 1.5 × ULN;
    3. Patients with moderate to severe renal insufficiency ( \< 60 ml/min/1.73m2, calculation of eGFR using the simplified MDRD equation);
    4. Screening positive for (HIV) or a positive syphilis antibody test, active virus infection (hepatitis B surface antigen positive and HBV-DNA load above the lower limit of detection) or active virus infection (HCV antibody positive and HCV-RNA load above the lower limit of detection).
  11. Participation in a clinical trial of any other drug or medical device (treated with a drug or medical device in a clinical trial) within 3 months prior to screening.
  12. Have undergone bronchial thermoplasty within 12 months prior to screening or plan to undergo this treatment during the study period.
  13. Currently using or have used anti-interleukin-5 (IL-5) monoclonal antibody, anti-interleukin-4/13 (IL-4/13) monoclonal antibody, anti-interleukin-4 receptor (IL-4R) monoclonal antibody, anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, anti-IgE monoclonal antibody within 12 weeks prior to screening or within 5 half-lives of the drug, whichever is longer.
  14. Patients who have previously received treatment with HSK31858 tablets or similar products of DPP1 inhibitors.
  15. Patients who have used a strong inducer or inhibitor of within 14 days or 5 half-lives prior to the first product administration, whichever is longer.
  16. Having received a drug that may cause hyperkeratosis of the skin (e.g., tumor necrosis factor alpha antagonist) within 4 weeks prior to screening.
  17. Comorbidities associated with the development of non-hereditary palmoplantar keratoderma (e.g., myxedema, chronic lymphoedema).
  18. Comorbid periodontal disease that, in the judgement of the investigator, has an impact on the study.
  19. Currently smoking subjects or subjects who quit smoking within 6 months prior to the screening visit; previous smoking subjects with a smoking history >10 pack-year = packs per day × years of smoking (Note: 1 pack = 20 cigarettes, 10 pack-year = 1 pack/day × 10 years or 1/2 pack/day × 20 years).
  20. History of drug use, or substance abuse within 2 years prior to screening.
  21. Pregnant, or planning to become pregnant during the study, or breastfeeding.
  22. Subjects judged by the investigator to be unsuitable for participating in this trial for any reason.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
219 participants (estimated)

Study arms

  • Experimental
    HSK31858 20mg

    multiple oral doses: 20mg/d for 48w

    Drug: HSK31858

  • Experimental
    HSK31858 40mg

    multiple oral doses: 40mg/d for 48w

    Drug: HSK31858

  • Placebo comparator
    placebo

    multiple oral doses for 48w

    Drug: Placebo

Interventions

  • HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 48-week treatment period in patients with bronchial asthma

  • DrugPlacebo

    the placebo comparator of study

06

What researchers measure

Primary outcomes

  1. The annualized asthma exacerbation rate within 24 weeks

    Total number of acute exacerbations of bronchial asthma occurring within 24 weeks of study dosing / actual length of follow-up within 24 weeks of dosing

    Time frame: 24-week treatment period

Secondary outcomes

  1. The annualized asthma exacerbation rate within 48 weeks

    Total number of acute exacerbations of bronchial asthma occurring within 48 weeks of study dosing / actual length of follow-up within 48 weeks of dosing

    Time frame: 48-week treatment period

  2. Time to first acute exacerbation of bronchial asthma

    Length of time from randomization to first acute exacerbation of bronchial asthma within 48 weeks of treatment

    Time frame: 48-week treatment period

  3. Change from Baseline in forced expiratory volume in 1 second (FEV1)

    Change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) at each clinical visit during the treatment period

    Time frame: 48-week treatment period

  4. Change from baseline in peak expiratory flow(PEF)

    Change from baseline in peak expiratory flow (PEF) at each clinical visit during the treatment period

    Time frame: 48-week treatment period

  5. Change from baseline in Asthma Control Test (ACT)

    Change from baseline in Asthma Control Test (ACT) score at each clinical visit during the treatment period.The ACT score is a questionnaire designed to assess the level of asthma control, including the impact of asthma on daily life, number of breathlessness episodes, asthma symptoms, use of rescue medication, and self-assessment of asthma control. The ACT score is a questionnaire designed to assess the level of asthma control, including the impact of asthma on daily life, number of breathlessness episodes, asthma symptoms, use of rescue medication, and self-assessment of asthma control.

    Time frame: 48-week treatment period

  6. Change from baseline in the 5-item Asthma Control Questionnaire (ACQ-5)

    Change from baseline in the 5-item Asthma Control Questionnaire (ACQ-5) score at each clinical visit during the treatment period.5-item Asthma Control Questionnaire(ACQ-5) is a scoring scale used to assess asthma control in patients over the past week. It addresses asthma-related symptoms and consists of five items, each scored on a scale of 0 to 6, with higher scores indicating poorer control。Take the average score of 5 questions: \<0.75 points indicate that asthma has been fully controlled; a score between 0.75 and 1.5 indicates that asthma is well controlled; and a score of \>1.5 indicates that asthma is not controlled.

    Time frame: 48-week treatment period

  7. Change from baseline in 24-h sputum weight

    Change from baseline in 24-h sputum weight at each clinical visit during the treatment period

    Time frame: 48-week treatment period

  8. The number of puffs of rescue medication used

    The number of puffs of rescue medication used at each clinical visit during the treatment period

    Time frame: 48-week treatment period

  9. Change from baseline in Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ)

    Change from baseline in Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) scores after 12, 24, 36, and 48 weeks of treatment.The Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) is dedicated to assessing the quality of daily life in adults with asthma. The Asthma Quality of Life Questionnaire is a 7-point scale, with 1 indicating the worst and 7 the best. The sum of each item scores is the total score. The maximum total score is 105, with higher scores indicating better asthma control and lower scores indicating poorer quality of life.

    Time frame: 48-week treatment period

  10. The proportion of patients without acute exacerbation of bronchial asthma

    The proportion of patients without acute exacerbation of bronchial asthma after 24 and 48 weeks of treatment

    Time frame: 48-week treatment period

  11. Patient Global Impression of Change (PGIC)

    Patient Global Impression of Change (PGIC) after 24 and 48 weeks of treatment.The PGIC scale is an assessment of the overall change in the patient's condition since the start of the study and is rated on a 7-point scale: a score of 1 represents extreme improvement, 2 represents significant improvement, 3 represents slight improvement, 4 represents no improvement, 5 represents slight deterioration, 6 represents significant deterioration and 7 represents critical deterioration.

    Time frame: 48-week treatment period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2026, 17 months after the start.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 17 months is close to that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Oct 22, 2024
Primary completionEst.
Mar 22, 2026
CompletionEst.
Sep 20, 2026
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06637254
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 22, 2024
Primary completion
Mar 22, 2026 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Dec 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florensocatib

Start the discussion